Starla Allen, DO
Family Medicine · Fairfax, OKNPI 1992071179
Payments from drug & device makers
Across 527 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$792
- Lilly USA, LLC$773
- Bayer$654
- Boehringer Ingelheim$517
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,505100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,544 |
| AbbVie(2 entities) | 100 | $1,011 |
| Novo Nordisk | 54 | $792 |
| Lilly USA, LLC | 40 | $773 |
| Bayer | 40 | $654 |
| Boehringer Ingelheim | 36 | $517 |
| Pfizer | 21 | $362 |
| GSK | 26 | $350 |
| Astellas Pharma US Inc | 12 | $296 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $293 |
| Amgen | 13 | $220 |
| Sanofi-aventis U.S. LLC | 12 | $202 |
| Aimmune Therapeutics, Inc. | 10 | $194 |
| Abbott | 10 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $162 |
| Exact Sciences | 8 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Antares Pharma, Inc. | 4 | $64 |
| Medtronic | 1 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Electromed, Inc. | 10 | $60 |
| Mylan Specialty L.p. | 2 | $57 |
| Currax Pharmaceuticals LLC | 4 | $56 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Novartis | 3 | $43 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Organogenesis Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Kaleo, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,505 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 118 | $148,156 |
| EliquisApixaban | 108 | $105,945 |
| OzempicSemaglutide | 52 | $70,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $58,223 |
| JardianceEmpagliflozin | 65 | $51,823 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $41,311 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $30,449 |
| ProliaDenosumab | 17 | $29,268 |
| LinzessLinaclotide | 34 | $28,273 |
| XareltoRivaroxaban | 25 | $25,911 |
| RybelsusSemaglutide | 19 | $22,041 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $18,520 |
| LyricaPregabalin | 12 | $13,570 |
| Hysingla ErHydrocodone Bitartrate | 24 | $13,187 |
| EntrestoSacubitril/Valsartan | 11 | $12,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $773 | $148,156118 claims |
| PfizerEliquis, Lyrica | $362 | $119,515120 claims |
| Novo NordiskOzempic, Rybelsus | $792 | $92,88471 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $350 | $76,74397 claims |
| Boehringer IngelheimJardiance | $517 | $51,82365 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,544 | $45,64859 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $202 | $41,31139 claims |
| AmgenProlia | $220 | $29,26817 claims |
| AbbVieLinzess | $1,011 | $28,27334 claims |
| Johnson & JohnsonXarelto | $11 | $25,91125 claims |
| NovartisEntresto | $43 | $12,94911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Fairfax
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.